checkAd

DGAP-News BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN

Nachrichtenquelle: EQS Group AG
06.05.2021, 18:00  |  148   |   |   

DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous
BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN

06.05.2021 / 18:00
The issuer is solely responsible for the content of this announcement.


Zwingenberg, Germany, May 6th, 2021

Genome Editing Tool Developed by BRAIN

- Novel CRISPR Cas system

- Holding significant economic potential

- Different commercialization models currently being explored


BRAIN Biotech AG has successfully completed the first development phase for a novel genome editing CRISPR Cas system applying its advanced metagenomics sequencing and protein engineering capabilities. BRAIN's technology enabled by a novel and independent Non-CAS9-Nuclease will significantly speed up in-house developments and promises significant economic upside.

Genome editing has lately become one of the most exciting technologies in biotechnology. It allows for the directed and precise insertion, deletion or modification in the genome of a living organism. The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science.

BRAIN has developed a novel CRISPR Cas tool using metagenomics sequencing and protein engineering to isolate a Non-Cas9 genome editing nuclease. Our scientist have achieved this breakthrough employing their expertise and practical R&D experience with genome editing knowledge available throughout the BRAIN Group.

BRAIN's novel CRISPR associated nuclease has been validated internally as well as with partners and it has demonstrated DNA targeting activity in selected bacteria, fungi and yeast. Activity in plants has been achieved but still needs to be validated. Genome editing tests for additional application fields such as mammalian cell lines have been initiated and a first IP application to protect our nuclease sequence is already submitted.

Dr. Michael Krohn, Head R&D at BRAIN Biotech AG emphasizes: "The market for genome editing tools based on the CRISPR Cas mechanism is just emerging and offers significant growth opportunities. Our BRAIN developed CRISPR associated nuclease will give us internal freedom to operate and we are currently exploring its potential beyond microorganisms and plants. This success is further evidence of our stated mission to create Breakthroughs. It makes me very proud that the innovative spirit of our scientists keeps creating new projects with real breakthrough potential."

Seite 1 von 4
BRAIN Biotech Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de




Diskussion: B.R.A.I.N. Biotechnology kaufen?
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN 06.05.2021 / 18:00 The issuer is solely responsible for the content of this announcement. Zwingenberg, Germany, May 6th, 2021Genome …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel